EXAGEN INC.
XGNNasdaqHealthcare · Services-Medical Laboratories · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $66.6M | $55.6M | $52.5M | $45.6M | $48.3M | $42.0M |
| Operating income | −$14.1M | −$13.6M | −$22.8M | −$46.1M | −$24.1M | −$15.2M |
| Net income | −$20.0M | −$15.1M | −$23.7M | −$47.4M | −$26.9M | −$16.7M |
| Total assets | $58.0M | $44.7M | $56.9M | $86.2M | $123.4M | $78.4M |
| Total liabilities | $40.6M | $35.1M | $34.3M | $43.8M | $38.5M | $36.5M |
| Equity | $17.4M | $9.5M | $22.7M | $42.5M | $84.9M | $41.8M |
| EPS (diluted) | $-0.93 | $-0.83 | $-1.34 | $-2.77 | $-1.68 | $-1.32 |
| Shares out. | 17.9M | 17.2M | 16.8M | 16.2M | 12.7M | 12.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −21.1%
- Net margin
- −30.0%
- Return on equity
- −114.3%
- Return on assets
- −34.4%
- Return on capital (ROCE)
- −32.1%
- Liabilities / assets
- 69.9%
- Debt / equity
- 2.33×
- Book value / share
- $0.97
- Revenue growth (YoY)
- 19.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -14.91distress
- Accruals / assets
- −10.9%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 14, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Black Jeffrey G.Officer — Chief Financial Officer | Mar 12, 2026 | Grant | 75,000 | $3.16 |
| Aballi JohnOfficer — President and CEO | Mar 12, 2026 | Grant | 150,000 | $0.00 |
| Aballi JohnOfficer — President and CEO | Mar 3, 2026 | Sell | 15,698 | $3.62 |
| Aballi JohnOfficer — President and CEO | Feb 24, 2026 | Sell | 11,430 | $3.61 |
| Black Jeffrey G.Officer — Chief Financial Officer | Feb 24, 2026 | Sell | 1,584 | $3.61 |
| Aballi JohnOfficer — President and CEO | Oct 16, 2025 | Sell | 31,787 | $11.82 |
| Black Jeffrey G.Officer — Chief Financial Officer | Sep 2, 2025 | Sell | 20,466 | $9.79 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 716,154 | 1.0 | -1.2% |
| Apr 30, 2026 | 724,679 | 3.9 | -0.7% |
| Apr 15, 2026 | 729,740 | 3.8 | -52.5% |
| Mar 31, 2026 | 1.5M | 5.9 | +34.3% |
| Mar 13, 2026 | 1.1M | 3.1 | +6.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 11, 2026
- Director / officer changeApr 23, 2026
- Results of operationsMar 10, 2026
- Results of operations · Other material eventJan 12, 2026
- Results of operationsNov 4, 2025
- Results of operationsJul 29, 2025
- Director / officer change · Other material eventJul 17, 2025
- Shareholder voteJun 11, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13GMay 27, 2026
- SCHEDULE 13G/AMay 20, 2026
- S-8May 12, 2026
- 10-QMay 11, 2026
- 8-KMay 11, 2026
- ARSApr 27, 2026
- DEFA14AApr 27, 2026
- DEF 14AApr 27, 2026
- 8-KApr 23, 2026
- 3/AFORM 3/AApr 21, 2026
- 3FORM 3Mar 16, 2026
- 4FORM 4Mar 16, 2026
- 4FORM 4Mar 16, 2026
- 10-KMar 10, 2026
- 8-KMar 10, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.